Argent Biopharma ( (AU:RGT) ) just unveiled an announcement.
Argent BioPharma has announced positive results from a Phase IIb clinical trial of CimetrA®, which confirmed its strong safety profile and potential efficacy in treating COVID-19. The trial demonstrated faster recovery times and symptom improvement in patients treated with CimetrA® compared to placebo, alongside promising anti-inflammatory effects. These findings suggest CimetrA® could have broader applications in treating other inflammatory and autoimmune conditions, reinforcing its potential as a well-tolerated adjunct therapy.
More about Argent Biopharma
Argent BioPharma Ltd. operates in the biopharmaceutical industry, focusing on developing therapeutic solutions for inflammatory and autoimmune diseases. The company is primarily engaged in advancing its product CimetrA®, which has shown potential in modulating inflammatory pathways and improving patient outcomes.
YTD Price Performance: -50.86%
Average Trading Volume: 135,660
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.88M
Learn more about RGT stock on TipRanks’ Stock Analysis page.